Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.53 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914823 | 0.88 | PARP1 (0.43) | KMT2AMEN1KDM4EALDH1A1RAB9A | |
| SCHEMBL914848 | 0.88 | SLC2A1 (0.45) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL914669 | 0.88 | SLC2A1 (0.45) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL914473 | 0.87 | KMT2A (0.44) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL914311 | 0.87 | PARP1 (0.43) | KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL914256 | 0.87 | KMT2A (0.44) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL914372 | 0.87 | PARP1 (0.43) | KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL12971898 | 0.85 | RHEB (0.56) | RHEBSLC6A12KMT2ASIGMAR1TMEM97 | |
| SCHEMBL913976 | 0.84 | KMT2A (0.44) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL914072 | 0.83 | SMYD3 (0.47) | KMT2AMEN1KDM4EALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | RHEB 3019/4885SLC6A12 1226/4885KMT2A 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.